How I Treat Metastatic Hormone-Sensitive Prostate Cancer?

Deepak Dabkara¹  Debapriya Mondal¹  Joydeep Ghosh¹  Bivas Biswas¹  Sandip Ganguly¹

¹Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

Abstract

Androgen deprivation therapy (ADT) combined with docetaxel or antiandrogens (abiraterone, enzalutamide, or apalutamide) improved the outcomes in men with metastatic hormone-sensitive prostate cancer (mHSPC). When multiple options are available, the dilemma remains how to choose among these options. Similarly, issues of bone health, long-term side effects of therapies, and hereditary risk need to be discussed for comprehensive care. In the present article, we reviewed the relevant evidence for the treatment of mHSPC. ADT alone is not the current standard of care for most patients. In these times of plenty and price crisis, it is imperative to find the best option for treating these patients.

Introduction

In a proportion of prostate cancer patients, there is evidence of metastatic disease at diagnosis or the disease recurs as distant metastasis despite standard curative treatment. An Indian hospital-based study reported that ~70% of prostate cancer patients had metastasis at diagnosis.¹ The upfront management of men with metastatic hormone-sensitive prostate cancer (mHSPC) had been with only androgen deprivation therapy (ADT), either with medical or surgical castration.² However, this scenario has recently changed after the publication of phase III randomized control trials that combine other agents with ADT upfront and clinicians now have various options to choose from. Each of these agents such as docetaxel, abiraterone acetate, enzalutamide, and apalutamide combined with ADT has shown significant survival benefit over ADT in randomized clinical trials. There is a lack of direct evidence to suggest the best choice as none of the trials include a head-on comparison between the available options. Factors such as toxicity profile, cost, and physicians' and patients' preferences are vital in choosing one of these options over the other. In the present manuscript, we have proposed an algorithm (►Fig. 1) for the management of patients with mHSPC from the currently available, most relevant literature on the topic.

Androgen Deprivation Therapy

ADT can be offered in the form of bilateral orchiectomy (surgical castration) or medical castration. Bilateral orchiectomy may be appropriate when a rapid decline in testosterone is needed (e.g., worsening obstructive urinary symptoms and imminent cord compression) or when cost or compliance to medical castration is a concern. In medical castration with gonadotropin-releasing hormone (GnRH) agonists, a flare in serum testosterone may result from an initial short-term surge of luteinizing hormone (LH), worsening the symptoms. Antiandrogens (e.g., flutamide and bicalutamide) used for 2 to 4 weeks may be effective in preventing this flare phenomenon.³⁴ GnRH antagonist degarelix is not associated with this surge of LH and can be a substitute to a GnRH

DOI https://doi.org/10.1055/s-0041-1729725
ISSN 0971-5851

©2021. Indian Society of Medical and Paediatric Oncology.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
agonist when a rapid fall in serum testosterone is necessary. Incidence of severe cardiac adverse events may be lower with the use of degarelix compared with GnRH agonists, an ongoing prospective trial is comparing the risk of cardiovascular events with the use of GnRH agonists and antagonists. The newer oral agent relugolix that has shown better testosterone suppression and cardiovascular safety profile in a phase III randomized trial compared with leuprolide is another potential option for ADT.

ADT has several side effects that can diminish the quality of life, which include loss of lean body mass, obesity, sexual dysfunction, vasomotor instability, gynecomastia, fatigue, cardiovascular, and metabolic abnormalities. Another concerning side effect is bone demineralization, which can lead to osteoporotic fractures. Intermittent ADT is a strategy to reduce these adverse effects by pausing ADT when patients have responded to treatment and restarting at progression. A phase III intergroup trial did not find intermittent ADT noninferior to continuous ADT in respect of overall survival (OS). In spite of the theoretical advantage, intermittent ADT is not recommended for patients of mHSPC save for those with an elevated serum prostate-specific antigen (PSA) as the sole manifestation of disseminated prostate cancer, unless quality of life is the main expectation.

**Docetaxel**

The first evidence of benefit from a combination treatment was with docetaxel that had previously improved OS in patients of metastatic castration-resistant prostate cancer (mCRPC). The CHAARTED trial that accrued 790 patients with hormone-naive metastatic prostate cancer reported improved survival of patients with mHSPC when docetaxel was added to ADT compared with ADT alone. However, in a smaller study (GETUG-AFU15), docetaxel plus ADT did not improve survival in patients of mHSPC and reported more toxicities. This conflicting evidence was explained by the difference in the burden of disease between the patient populations enrolled in these studies; they also differed in the number of chemotherapy cycles used. In the CHAARTED study, the majority (65%) of the patients had high-volume disease. Those with high-volume disease had a significant OS benefit from adding docetaxel to ADT (median OS 51.2 months vs. 34.4 months, hazard ratio [HR] = 0.63; 95% confidence interval [CI]: 0.50–0.79; \( p < 0.001 \)), but this was not evident in patients with low-volume disease (HR: 1.04; 95% CI: 0.70–1.55; \( p = 0.86 \)). The arm C of the multarm, multistage platform, STAMPEDE trial showed a significant OS benefit for patients treated with the combination of docetaxel and ADT (median OS 60 months in ADT plus docetaxel vs. 45 months in ADT only [HR: 0.76; 95% CI: 0.62–0.94]).

---

**Table 1** Stratification by metastatic disease burden

<table>
<thead>
<tr>
<th>Trial</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHAARTED</td>
<td>Defined as: (i) four or more bone metastases on high volume bone scan, including one or more outside the vertebral bodies or pelvis, and/or (ii) visceral metastases</td>
</tr>
<tr>
<td>LATITUDE</td>
<td>Defined as meeting at least two of three high risk criteria: (i) Gleason score &gt;8, (ii) presence of ≥3 lesions on bone scan, (iii) presence of measurable visceral lesions</td>
</tr>
</tbody>
</table>
Abiraterone Acetate

Abiraterone acetate, an irreversible inhibitor of CYP17A1 which initially got approval for the treatment of mCRPC,21,22 reported OS benefit in mHSPC when added to ADT in two phase III trials, LATITUDE and STAMPEDE.23,24 The LATITUDE trial enrolled 1199 patients with treatment-naïve mHSPC with two or more high-risk features (Table 1) and compared ADT plus abiraterone with ADT alone and reported significantly better survival (HR: 0.66 [95% CI: 0.56–0.78]; p < 0.0001) in the abiraterone with ADT arm. Risk of radiographic progression was reduced by 53% with the addition of abiraterone (HR: 0.47 [95% CI: 0.39–0.55]; p < 0.001). Abiraterone significantly prolonged time to pain progression, next antineoplastic treatment, the start of cytotoxic therapy, PSA elevation (p < 0.001 for all comparisons), and next symptomatic skeletal event (p < 0.009). Most subgroups benefitted with abiraterone added to ADT with the possible exceptions of the patients with Eastern Cooperative Oncology Group performance status 2, age of 75 years or more, or with a Gleason score of <8. In a retrospective observational study from an Indian tertiary care cancer center, treatment outcomes were comparable to phase III studies in patients treated with ADT combined with abiraterone.25

The STAMPEDE trial that randomized 1917 patients with HSPC (52% metastatic) to receive abiraterone acetate with ADT (arm G) or ADT alone reported a 39% reduced death risk (HR: 0.61; 95% CI: 0.49–0.75) in patients with mHSPC. Further, the risk of treatment failure was also significantly reduced in patients receiving abiraterone (HR: 0.29 [HR: 0.29, 95% CI: 0.25–0.34]; p < 0.001). Interestingly, a post hoc subgroup analysis of OS in metastatic patients included in STAMPEDE found survival benefit with coadministration of abiraterone and ADT irrespective of risk (LATITUDE criteria) or volume (CHARTED criteria); although it required four times the number of high-risk patients to be treated to find the OS benefit in the low-risk group.26

A prespecified direct comparison between the abiraterone and docetaxel arms of STAMPEDE did not show a difference in OS, prostate cancer-specific survival, and symptomatic skeletal events. Frequency of Grade 3 and 4 toxicities was comparable in both arms but comprised different toxicities. Neutropenia of all grades and febrile neutropenia occurred more frequently with docetaxel, while endocrine, cardiovascular, hepatic disorders, and hypokalemia were more common with abiraterone.27

**Novel Androgen Receptor Antagonists**

Enzalutamide, a second-generation androgen receptor inhibitor initially approved for the treatment of CRPC,28,29 has been explored as a treatment option combined with ADT in the mHSPC setting in two phase III trials.30,31 Interim analysis of the ENZAMET trial showed a significant OS benefit in patients treated with enzalutamide compared with those who received only ADT (HR = 0.67, p < 0.002). In the ARCHES trial, median radiographic progression-free survival (rPFS) for the placebo plus ADT arm was 19.4 months (95% CI: 16.6, NR, not reached), whereas median rPFS was not reached for the enzalutamide arm (HR: 0.39; 95% CI: 0.30, 0.50; p < 0.0001). The enzalutamide arm also had a statistically significant improvement in time to initiate a new systemic treatment (HR: 0.28; 95% CI: 0.20, 0.40; p < 0.0001).

On December 16, 2019, the US Food and Drug Administration (FDA) approved enzalutamide for patients with mHSPC. In the TITAN trial,32 a benefit for apalutamide was shown for men with both high-volume and low-volume metastatic disease. There was a significant improvement in rPFS (HR: 0.48; 95% CI: 0.39–0.60), and the risk of radiographic progression or death was reduced by 52%. In the apalutamide arm, the median rPFS was not reached and the same was 22.1 months in the placebo arm. Importantly, apalutamide showed a significant improvement in OS (HR: 0.67; 95% CI: 0.51–0.89), and reduced the risk of death by 33%. Median OS was not reached for either apalutamide or placebo groups. Apalutamide was approved for the treatment of mHSPC in the United States in September 2019.

In randomized trials, 0.5% of the patients receiving enzalutamide experienced seizures, while fall and fractures, ischemic heart disease, and posterior reversible encephalopathy syndrome remain other concerning side effects.33 In the TITAN trial, 4% of the patients receiving apalutamide had ischemic cardiac events. Apalutamide has also been associated with falls, fractures, and cardiac events in clinical trial experience.34

**Bone Health**

Long-term ADT has been shown to adversely affect bone mineral density (BMD) and raise pathological fracture risk in men. A large observational study found that prostate cancer patients have significantly higher fracture risk when they receive ADT (19.4 vs. 12.6%; p < 0.001).35 Metastatic prostate cancer patients have bone involvement in an estimated 90% of cases,36 and evidence suggests that men with metastatic prostate cancer have a higher incidence of osteopenia and osteoporosis compared with age-matched
control populations even prior to starting ADT. The National Institute for Health and Care Excellence UK guidelines recommend evaluation of fracture risk for all men receiving ADT and that those found to have osteoporosis should be offered treatment. The European Association of Urology, European Society for Radiotherapy (RT) and Oncology and International Society for Geriatric Oncology guidelines recommend BMD assessment prior to starting long-term ADT. In noncancer populations, FRAX, a fracture risk assessment tool, is commonly used to calculate the 10-year probability of major osteoporotic fracture (spine/hip/forearm/humeral fractures) to warrant the need for BMD assessment and/or treatment. The FRAX algorithm is useful in choosing metastatic prostate cancer patients who require early bone-directed therapy. However, there remains controversy regarding the benefit of using bone-directed therapy in men with mHSPC as compared with mCRPC. The STAMPEDE trial, in which high risk prostate cancer patients with and without osseous metastases were enrolled, the addition of zoledronic acid (ZA) to standard care failed to improve OS, while the addition of ZA to the arm that combined docetaxel to standard care did not show any advantage in failure free survival, skeletal related events (SREs), or OS. In the CALGB 90202, the use of ZA for HSPC was not associated with a decrease in SRE risk compared with treatment initiation after progression to CRPC.

Evidence with the use of denosumab, a fully human monoclonal antibody immunoglobulin G2 against Receptor activator of nuclear factor kappa-B ligand (RANK-L), is inadequate in mHSPC compared with mCRPC where its role is established. Denosumab is FDA approved for the prevention of bone loss and fractures during ADT based on a phase III study in patients with nonmetastatic prostate cancer receiving ADT, where denosumab improved BMD by 6.7% and reduced fracture risk (1.5 vs. 3.9%) compared with placebo.

In view of lack of evidence to support the use of bisphosphonates or denosumab in combination with androgen receptor targeted agents or chemotherapy in patients with mHSPC, routine use of bone-directed therapy is not recommended, but in men with osteoporosis or higher fracture risk detected prior to initiating ADT, such treatment should be considered.

The National Osteoporosis Foundation guidelines recommended daily calcium (1,000–1,200 mg) and Vitamin D3 (400–1,000 IU) supplementation along with additional treatment for men aged 50 years or older with osteopenia (T-score between 1.0 and 2.5 at the femoral neck, total hip, or lumbar spine by dual-energy X-ray absorptiometry [DEXA] scan) and a 10-year probability of hip fracture >3% or a 10-year probability of a major osteoporosis-related fracture >20%. In our practice, we initiate treatment with ZA (5 mg IV annually) or with denosumab (60 mg subcutaneous every 6 months) when the fracture risk derived from BMD and FRAX score (risk of hip fracture >3%, or risk of major osteoporotic fracture >20%) necessitates drug therapy. A baseline DEXA scan before the start of therapy and another after 1 year of therapy is recommended to monitor treatment response.

Role of Radiotherapy

The benefit of local therapy in conjunction with ADT for those presenting with mHSPC has been a subject of debate. The role of local RT concurrent with ADT has been tested in two randomized trials; among them, the phase III HORRAD trial randomized 432 men with primary metastatic prostate cancer with bone metastases and a serum PSA >20 ng/mL to ADT with or without external beam RT. At a median follow-up of 47 months, median OS did not improve from the addition of RT (45 vs. 43 months, HR: 0.90; 95% CI: 0.70–1.14); however, the addition of RT prolonged the median time to PSA progression (median: 15 vs. 12 months, HR: 0.78; 95% CI: 0.63–0.97). An unplanned subgroup analysis suggested that men with fewer than five metastases might have survival benefits (HR: 0.68; 95% CI: 0.42–1.10) when treated with RT in conjunction with ADT.

Survival benefit for RT to the prostate for unselected men with newly diagnosed metastatic prostate cancer was also not demonstrated in the phase III STAMPEDE trial, but there was an improvement in failure-free survival (3-year failure-free survival 32 vs. 23%, HR: 0.76; 95% CI: 0.68–0.84).

In a prespecified subgroup analysis, OS benefit was seen with RT in the men with a low metastatic burden (CHAARTED definition) at diagnosis (3-year survival 81 vs. 73%, HR for death 0.68, 95% CI: 0.52–0.90) but not in those with a high metastatic burden (HR: 1.07; 95% CI: 0.90–1.28).

Pooled results of both trials found ~7% improvement in survival in men with fewer than five bone metastases, along with an overall improvement in biochemical progression-free survival (HR: 0.74; 95% CI: 0.67–0.82) and failure-free survival (HR: 0.76; 95% CI: 0.69–0.84).

Imaging and Assessment during Treatment

In the initial evaluation of men diagnosed with conventional imaging as mHSPC at presentation, there may be some role of next-generation imaging (positron-emission tomography–computed tomography [PET/CT], PET/magnetic resonance imaging [MRI], and whole-body MRI) to clarify the burden of disease and this can help to choose either multi-modality management of oligometastatic disease or systemic anticancer therapy alone, but prospective data to guide such decision are limited.

Men with mHSPC who receive systemic therapy require periodic assessments to identify signs and symptoms of disease progression, as well as the side effects of treatment (Table 2). Measurement of serum PSA at specific intervals is the mainstay of testing. The current National Comprehensive Cancer Network (NCCN) guideline recommends testing PSA every 3 to 6 months during treatment for metastatic prostate cancer. A rise in PSA values, or development of new symptoms, is the cue for a radiologic assessment. When PSA levels do not decline in response to therapy or rise, the adequacy of castrate status (defined as serum testosterone <50 ng/mL) should be checked.
ancestry), or to those with a strong family history of cancer.

(e.g., BRCA1 and BRCA2, Lynch mutation, Ashkenazi Jewish cancer, or localized disease with intraductal histology, as of high- or very high-risk regional or metastatic prostate cancer. The St. Gallen Advanced Prostate Cancer Consensus Conference 2019 have addressed the issues of genetic counseling and genetic testing for prostate cancer. The Philadelphia guidelines recommend genetic testing for all men with metastatic prostate cancer and for those with a family history of cancer with gene panels wherever feasible, which should include BRCA1/2 and DNA mismatch repair genes. The NCCN prostate cancer guidelines recommend offering genetic testing to men with a personal history of high- or very high-risk regional or metastatic prostate cancer, or localized disease with intraductal histology, as well as a family history of high-risk germline mutations (e.g., BRCA1 and BRCA2, Lynch mutation, Ashkenazi Jewish ancestry), or to those with a strong family history of cancer.

Genetic Testing in Prostate Cancer

It is important in prostate cancer to address the inherited component. A family history of prostate cancer and/or other cancers (e.g., breast cancer diagnosed at an age younger than 50 years, male breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and melanoma) may be associated with an increased risk of heritable prostate cancer. The St. Gallen Advanced Prostate Cancer Consensus Conference 2017 and the Philadelphia Prostate Cancer Consensus Conference 2019 have addressed the issues of genetic counseling and genetic testing for prostate cancer. The Philadelphia guidelines recommend genetic testing for all men with metastatic prostate cancer and for those with a family history of cancer with gene panels wherever feasible, which should include BRCA1/2 and DNA mismatch repair genes. The NCCN prostate cancer guidelines recommend offering genetic testing to men with a personal history of high- or very high-risk regional or metastatic prostate cancer, or localized disease with intraductal histology, as well as a family history of high-risk germline mutations (e.g., BRCA1 and BRCA2, Lynch mutation, Ashkenazi Jewish ancestry), or to those with a strong family history of cancer.

Clinical trials of poly-adenosine diphosphate-ribose polymerase inhibitors have shown promising responses in men with germline or somatic mutations in BRCA2, BRCA1, ATM, CHEK2, PALB2, and in other homologous recombination DNA repair genes. Olaparib and rucaparib have been approved by the FDA for men with mCRPC harboring these mutations. On the other hand, advanced prostate cancer patients with loss of DNA mismatch repair may benefit from treatment with immune checkpoint inhibitors. However, these genetic components do not currently have any implications for the treatment of mHSPC.

How to Choose One Option

The choice between chemohormonal therapy and combined androgen receptor-targeted therapy (abiraterone or enzalutamide or apalutamide) is difficult, owing to the similar efficacy outcomes (Table 3) in cross-trial comparisons. Differences in toxicities and costs rather than the subtle differences in efficacy end points might, at times, guide selection among the many choices approved in the first-line treatment of mHSPC. Docetaxel appears to be the most cost-effective and efficient approach in combination with ADT for men with high-volume mHSPC; it is given for a relatively shorter period of time—18 weeks with reversible albeit severe short-term chemotherapeutic toxicities. However, in men with low-volume disease, the evidence of benefit from adding docetaxel has been conflicting. Unfortunately, similar concerns with evidence of clear benefit in low-volume disease remain with abiraterone as well since its indication in low-volume disease is based on a post hoc analysis of STAMPEDE that was not powered to find an OS benefit for the low-risk population. A cost-effectiveness analysis from the US report docetaxel is a more cost-effective option than abiraterone in the treatment of mHSPC. Abiraterone is recommended daily until disease progression with a median time on treatment of ~33 months and is expected to be costlier for our population. Patient preferences and comorbidities often help in the decision-making process. Docetaxel usually is preferred for patients who wish for a shorter treatment time.

Table 2 Drugs and periodic monitoring

<table>
<thead>
<tr>
<th>Drug</th>
<th>Periodic monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Docetaxel</td>
<td>CBC and differential, LFT before each cycle</td>
</tr>
<tr>
<td>Abiraterone acetate+prednisolone</td>
<td>Baseline: CBC and differential, LFT, creatinine, glucose, electrolytes. For the first three cycles: monitor blood pressure, serum potassium, LFT, every 2 weeks. Before each outpatient visit (every 4 weeks): CBC and differential, LFT, creatinine, glucose, electrolytes, regular monitoring of BP</td>
</tr>
<tr>
<td>Enzalutamide</td>
<td>Baseline: CBC and differential, creatinine, electrolytes, blood pressure, ECG Before each outpatient visit: blood pressure, serum creatinine, electrolytes, ECG</td>
</tr>
</tbody>
</table>

Abbreviations: BP, blood pressure; CBC, complete blood count; ECG, electrocardiogram; LFT, liver function tests.

Table 3 Comparison of overall survival of trials (not head-to-head) in first-line treatment of metastatic hormone-sensitive prostate cancer

<table>
<thead>
<tr>
<th>Agent</th>
<th>Docetaxel</th>
<th>Abiraterone</th>
<th>Enzalutamide</th>
<th>Apalutamide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
<td>CHAARTED&lt;sup&gt;14&lt;/sup&gt;</td>
<td>STAMPEDE&lt;sup&gt;18,19&lt;/sup&gt;</td>
<td>LATITUDE&lt;sup&gt;25&lt;/sup&gt;</td>
<td>ENZAMET&lt;sup&gt;30&lt;/sup&gt;</td>
</tr>
<tr>
<td>Arm C M1 patients</td>
<td>57.6 vs. 47.2 months</td>
<td>59.1 vs. 43.1 months</td>
<td>53.3 vs. 36.5 months</td>
<td>0.61 (0.49–0.75)</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>0.67 (0.52–0.86)</td>
<td>0.67 (0.51–0.89)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.72 (0.59–0.89)</td>
<td>0.76 (0.62–0.92)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>10.4 months</td>
<td>16 months</td>
<td>15 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OS-HV</td>
<td>0.63 (0.50–0.79)</td>
<td>0.81 (0.64–1.02)</td>
<td>0.60 (0.46–0.78)</td>
</tr>
<tr>
<td></td>
<td>0.62 (0.52–0.78)</td>
<td>0.66 (0.56–0.78)</td>
<td>0.80 (0.59–1.07)</td>
<td>0.68 (0.50–0.92)</td>
</tr>
<tr>
<td>OS-LV</td>
<td>1.04 (0.70–1.55)</td>
<td>0.76 (0.54–1.07)</td>
<td>0.72 (0.47–1.10)</td>
<td>0.64 (0.42–0.97)</td>
</tr>
<tr>
<td></td>
<td>0.43 (0.26–0.72)</td>
<td>0.67 (0.34–1.32)</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: HV, high volume; LV, low volume; mHSPC, metastatic hormone-sensitive prostate cancer; OS, overall survival. Figures are hazard ratios with 95% confidence intervals from select phase III trials in the upfront treatment of mHSPC.
Patients with preexisting hypertension, hepatic derangement, and metabolic abnormalities may not be suitable candidates for abiraterone. Further, there is nothing to suggest that abiraterone offers any benefit in the population considered ineligible for docetaxel—those with poor performance status and the elderly, as a benefit in these subgroups was unclear in the LATITUDE trial. Enzalutamide, the new entrant in this setting, has proven to be effective for both low- and high-volume disease and is an attractive option for those wishing to avoid chemotherapy and steroids. The unique adverse events with enzalutamide such as falls, seizures, syncope, cognitive, and mental impairment warrant caution while selecting patients. In general, patients who wish to avoid chemotherapy at all costs and wish to minimize hospital visits should be offered an androgen receptor-targeted therapy. In absence of prospective evidence, the question of whether we should add docetaxel or abiraterone to ADT in patients with low-volume or low-risk mHSPC remains a difficult one and such treatments should be offered with caution.

Patients of mHSPC with a low burden of bone metastases (four or fewer bone metastases, with none outside the vertebral bodies or pelvis) and no visceral metastases may be offered RT to the prostate in conjunction with systemic therapy. Finally, there are groups of patients who may do well with ADT alone, even intermittently, sometimes for many years. The ultimate choice for an individual patient largely depends on the oncologist elaborating risks and benefits of each available option while considering the patient's comorbid conditions, access to treatment, financial aspects, and preference.

Table 4: Comparison of unique factors and toxicities between upfront options

<table>
<thead>
<tr>
<th></th>
<th>Docetaxel</th>
<th>Abiraterone</th>
<th>Enzalutamide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length of treatment</td>
<td>Shorter</td>
<td>Longer</td>
<td>Longer</td>
</tr>
<tr>
<td>Finances</td>
<td>Relatively inexpensive, likely to be covered by insurance</td>
<td>Costlier, likely to be out of pocket</td>
<td>Costlier, likely to be out of pocket</td>
</tr>
<tr>
<td></td>
<td>Rs. 10,000–15,000 per cycle for 6 cycles</td>
<td>Rs. 10,000 and above per month</td>
<td>Rs. 20,000 and above per month</td>
</tr>
<tr>
<td>Salient toxicities</td>
<td>Neutropenia, peripheral neuropathy, alopecia</td>
<td>Liver enzyme elevation, hypokalemia, hypertension</td>
<td>CNS-seizure, PRES, cognitive, falls, and fractures</td>
</tr>
<tr>
<td>Disease burden</td>
<td>High</td>
<td>High</td>
<td>Any</td>
</tr>
<tr>
<td>Steroid</td>
<td>Not required</td>
<td>Required</td>
<td>Not required</td>
</tr>
</tbody>
</table>

Abbreviations: CNS, central nervous system; PRES, posterior reversible encephalopathy syndrome.

What I Follow in My Practice

Most of the patients do present to our center with PSA, histopathology, and some imaging (mainly MRI pelvis and bone scan). I generally review histopathology at our center as per the institutional policy unless the report is from a reputed cancer center or oncopathologist. If the available imaging already suggests metastatic disease, I do not advise Ga prostate-specific membrane antigen (PSMA) PET/CT. I use CT scans of the thorax, abdomen, pelvis, and bone scan to assess metastatic disease volume. For patients who present with PSA rise after past curative treatment, I prefer PSMA PET/CT scan. I discuss medical and surgical castration with my patients and the cost of treatment is often the main deciding factor between the two. I recommend a baseline BMD before starting ADT. If the FRAX score is suggestive of a high risk of fracture, they are offered ZA 5 mg once a year. For high-volume disease, I discuss with the patients all three options (ADT with docetaxel or abiraterone or enzalutamide).

Conclusion

The oncologist’s armamentarium for treating mHSPC is rapidly expanding as newer evidence demonstrates that combination therapy with one among docetaxel, abiraterone acetate, enzalutamide, or apalutamide provides a significant OS benefit when compared with ADT alone. The availability of many options with unique toxicity profiles allows oncologists flexibility in choosing the right option for individual patients. We await the results of ongoing randomized studies of darolutamide or further intensification of treatment to provide further guidance for clinicians. For now, it is rational to conclude that upfront combination approaches are the new standard of care for men with mHSPC, and some patients with low-volume disease may benefit from the addition of RT, while ADT alone remains an option only in patients who are either not fit for the combination options or have unacceptable toxicities.

Financial Support and Sponsorship

Nil.
Conflicts of Interest
There are no conflicts of interest.

References
11 Klotz L, O’Callaghan CJ, Ding K, et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. JCO 2011;29(7(Suppl):3